Midface contour and volume in Chinese adults treated with Sculptra™ over long term
Official title: A Non-interventional, Multi-center Study to Evaluate the Long-term Safety and Effectiveness of Sculptra™ for the Correction of Midface Volume Deficit and/or Midface Contour Deficiency in the Chinese Population
Run by Galderma R&D · NCT07891767 · Data updated 2026-11-12
This study tests whether Sculptra™ used in standard practice can safely improve midface fullness over about two years in Chinese adults who have previously received the treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Galderma R&D Industry-sponsored |
| Locations | 1 site (Guangzhou) |
| Status | Recruiting |
| Started | October 2026 |
| Main results expected | April 2028 |
| Study ends | April 2028 |
| Registry record updated | October 23, 2026 |
| Trial ID | NCT07891767 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older of Chinese origin who have had prior midface Sculptra™ treatment 11–12 months before screening and have retained treatment records.
✕Probably not a fit
Individuals who recently received other fillers within the past year or those who do not have prior midface Sculptra™ treatment may not experience documented benefits in this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a non-interventional, multi-center study designed to observe long-term safety and effectiveness of Sculptra™ for midface volume deficit and contour deficiency in Chinese adults. Data will be collected for up to 24 months after the initial treatment, including 12 months of retrospective information and 12 months of prospective follow-up. Participants must have had a prior midface Sculptra™ treatment 11–12 months before screening, with no recent fillers in the prior year, and they may be treated in routine clinical practice rather than a controlled setting. The study does not specify a new intervention and relies on real-world use to assess outcomes and safety in this population.
Why it matters
Potential benefit: If successful, the study could support the long-term safety and effectiveness of Sculptra™ for midface augmentation in Chinese adults.
How similar studies have gone: Prior real-world use of Sculptra™ in other populations has shown varying safety and effectiveness; this study provides population-specific long-term observational data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Men or women aged 18 years or older of Chinese origin. 2. Subjects who, independently of this study, received initial Sculptra treatment in the midface, with or without other facial areas, 11-12 months before screening, with relevant treatment records retained by the clinic. Exclusion Criteria: 1. Received any other sort of hyaluronic acid fillers and collagen-based filler in the midface within 1 year after the first Sculptra treatment in the midface. 2. Received treatment with semi-permanent filler in the midface within 1 year before the first Sculptra treatment in the midface up to Day 1. 3. Received treatment with permanent filler in the midface. 4. Participation in any other clinical study within 30 days before Day 1.
Where it's running
-
Dermatology Hospital of Southern Medical University
Guangzhou, China Recruiting
Study contacts
- Study coordinator: Galderma Research & Development
- Email: Clinical.Studies@galderma.com
- Phone: +8621 23159790
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Mosaic Injectable Dermal Implant for Midface Volume Deficit
This study tests whether the Mosaic Injectable Dermal Implant safely adds volume to the midface in adults 22 and older with age-related volume loss.
-
Injectable hyaluronic acid filler for lips, nasolabial folds, and midface volume
The study tests three concentrations of an injectable hyaluronic acid filler to see if it safely and effectively enhances lips, smooths nasolabial folds, and adds midface volume in adults.
-
Alcarisa (hyaluronic acid) injections to restore mid-face volume
Doctors will try Alcarisa hyaluronic acid injections to restore mid-face volume in adults 30 to 65 with moderate to severe cheek volume loss.
-
Assessing a new injectable gel for improving mid-face volume
This study is testing a new injectable gel to see if it can safely and effectively restore volume in the mid-face for adults who have lost fullness due to aging, comparing it to an existing treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.